Citations

Clear

4847 citation(s) found for "Tu, Eric".

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231
Hayashi, Robert J. , Hermiston, Michelle L. , Wood, Brent L. , Teachey, David T. , Devidas, Meenakshi , Chen, Zhiguo , Annett, Robert D. , Asselin, Barbara L. , August, Keith J. , Cho, Steve , Galardy, Paul J. , Harker‐Murray, Paul , Jaju, Alok , Lam, Allison, Miles, Rodney R., Okada, Maki , Patel, Samir , Schechter, Tal , Shimano, Kristin A. , Singh, Neelam, Steele, Amii C., Sulis, Maria Luisa , Vargas, Sarah , Winter, Stuart S. , Wood, Charlotte, Loh, Mignon L. , Raetz, Elizabeth A. , Bollard, Catherine M. , Allen, Carl E. , August, Keith , Freedman, Jason Lawrence , Galardy, Paul J , Harker-Murray, Paul , Horton, Terzah M. , Jaju, Alok I , Messinger, Yoav H , Okada, Maki , Schafer, Eric S , Shimano, Kristin A , Sulis, Maria L , Winter, Stuart S , Zweidler-McKay, Patrick A , Loh, Mignon L , Hunger, Stephen P , Raetz, Elizabeth A , Bollard, Catherine M , Allen, Carl E , Wood, Brent L , Devidas, Meenakshi , Dunsmore, Kimberly P , Messinger, Yoav H. , Schafer, Eric S. , Hunger, Stephen P.

Mayo Clinic

Blood | March 8, 2024 | Volume: 143 | Issue: 20 | Pages: 2053-2058

10.1182/blood.2023021184 | PMID 38457359 Get It

Abstract Defining prognostic variables in T-lymphoblastic lymphoma (T-LL) remains a challenge. AALL1231 was a Children’s Oncology Group phase 3 clinical trial for newly diagnosed patients with T acute lymphoblastic leukemia or T-LL, randomizing children and young adults to a modified augmented Berlin-Frankfurt-Münster backbone to receive standard therapy (arm A) or with addition of bortezomib (arm B). Optional bone marrow samples to assess minimal residual disease (MRD) at the end of induction (EOI) were collected in T-LL analyzed to assess the correlation of MRD at the EOI to event-free survival (EFS). Eighty-six (41%) of the 209 patients with T-LL accrued to this trial submitted samples for MRD assessment. Patients with MRD <0.1% (n = 75) at EOI had a superior 4-year EFS vs those with MRD ≥0.1% (n = 11) (89.0% ± 4.4% vs 63.6% ± 17.2%; P = .025). Overall survival did not significantly differ between the 2 groups. Cox regression for EFS using arm A as a reference demonstrated that MRD EOI ≥0.1% was associated with a greater risk of inferior outcome (hazard ratio, 3.73; 95% confidence interval, 1.12-12.40; P = .032), which was independent of treatment arm assignment. Consideration to incorporate MRD at EOI into future trials will help establish its value in defining risk groups. CT# NCT02112916.
Sleep-related painful erections treated with sodium oxybate
Chaudhary, Hira, Zeidman, Eric J., Tashman, Yasemin, Chaudhary, Hira S, Zeidman, Eric, Punjani, Nahid

Mayo Clinic

Journal of Clinical Sleep Medicine | March 8, 2024 | Volume: 20 | Issue: 7 | Pages: 1209-1211

10.5664/jcsm.11120 | PMID 38456812 Get It

Acute pulmonary injury in hematology patients supported with pathogen-reduced and conventional platelet components
Wheeler, Allison P. , Snyder, Edward L. , Refaai, Majed A. , Cohn, Claudia S. , Poisson, Jessica , Fontaine, Magali J. , Sehl, Mary E. , Uhl, Lynne , Fenelus, Maly , Coyle, Thomas, Becker, Joanne , Jeng, Michael , Young, Pampee P. , OʼBrien, Jennifer , Schiller, Gary J. , Roback, John D. , Malynn, Elizabeth, Jackups, Ronald , Avecilla, Scott T. , Bentow, Stanley, Varrone, Jeanne, Fontaine, Magali , Fenelus, Maly , Jeng, Michael , Spencer, Bryan R , O'Brien, Jennifer J, Roback, John D , Avecilla, Scott T , Benjamin, Richard J , Cohn, Claudia S , Wheeler, Allison P , Nooka, Ajay K. , Spinella, Philip C. , Liles, Darla , Gehrie, Eric A , Spencer, Bryan R. , Johnson, Andrew, Liu, Kathy , Corash, Laurence M

Mayo Clinic

Blood Advances | March 6, 2024 | Volume: 8 | Issue: 9 | Pages: 2290-2299

10.1182/bloodadvances.2023012425 | PMID 38447116 Get It

Abstract Patients treated with antineoplastic therapy often develop thrombocytopenia requiring platelet transfusion, which has potential to exacerbate pulmonary injury. This study tested the hypothesis that amotosalen-UVA pathogen–reduced platelet components (PRPCs) do not potentiate pulmonary dysfunction compared with conventional platelet components (CPCs). A prospective, multicenter, open-label, sequential cohort study evaluated the incidence of treatment-emergent assisted mechanical ventilation initiated for pulmonary dysfunction (TEAMV-PD). The first cohort received CPC. After the CPC cohort, each site enrolled a second cohort transfused with PRPC. Other outcomes included clinically significant pulmonary adverse events (CSPAE) and the incidence of treatment-emergent acute respiratory distress syndrome (TEARDS) diagnosed by blinded expert adjudication. The incidence of TEAMV-PD in all patients (1068 PRPC and 1223 CPC) was less for PRPC (1.7 %) than CPC (3.1%) with a treatment difference of –1.5% (95% confidence interval [CI], –2.7 to –0.2). In patients requiring ≥2 PCs, the incidence of TEAMV-PD was reduced for PRPC recipients compared with CPC recipients (treatment difference, –2.4%; 95% CI, –4.2 to –0.6). CSPAE increased with increasing PC exposure but were not significantly different between the cohorts. For patients receiving ≥2 platelet transfusions, TEARDS occurred in 1.3% PRPC and 2.6% CPC recipients (P = .086). Bayesian analysis demonstrated PRPC may be superior in reducing TEAMV-PD and TEARDS for platelet transfusion recipients compared with CPC recipients, with 99.2% and 88.8% probability, respectively. In this study, PRPC compared with CPC demonstrated high probability of reduced severe pulmonary injury requiring assisted mechanical ventilation in patients with hematology disorders dependent on platelet transfusion. This trial was registered at www.ClinicalTrials.gov as #NCT02549222.
Osteoporosis is associated with anti-topoisomerase I positivity and glucocorticoids use in patients with systemic sclerosis
Midol, Charles , Wiebe, Edgar , Siegert, Elise , Huscher, Dörte , Béhal, Hélène, Matteson, Eric L. , Buttgereit, Frank , Sobanski, Vincent , Buttgereit, Frank , Sobanski, Vincent , Launay, David , Hachulla, É.

Mayo Clinic

Rheumatology | March 6, 2024 | Volume: 64 | Issue: 3 | Pages: 1270-1276

10.1093/rheumatology/keae142 | PMID 38452356 Get It

Abstract Objectives Patients with systemic sclerosis (SSc) are at increased risk for osteoporosis (OP) and associated fragility fractures. This study aimed to identify underlying risk factors for these conditions in patients with SSc. Methods This cross-sectional study was based on a large prospective cohort of patients with SSc using retrospectively collected bone health data. OP was defined as the presence of a T-score below -2.5 at the femoral neck or lumbar spine, a previous major osteoporotic fracture, or the prescription of anti-osteoporotic therapy. Results A total of 485 patients fulfilling the ACR/EULAR 2013 diagnostic criteria for SSc, followed in the Lille University Hospital, were included in the study. The prevalence of OP was 23%; fragility fractures occurred in 18% of patients. OP was associated with higher age, diffuse cutaneous subset, interstitial lung disease (ILD), anti-topoisomerase I positivity, treatment with glucocorticoids (GC) and DMARDs in univariable analysis. Multivariable analysis indicated that higher age (OR 1.06 [95%CI 1.04–1.08]), anti-topoisomerase I antibody positivity (OR 2.22 [1.18–4.16]) and treatment with GC (OR 4.48 [2.42–8.26]) were significantly and independently associated with OP. Conclusion Our study shows that OP risk in patients with SSc is determined by age, disease-related factors such as diffuse cutaneous subset, ILD and anti-topoisomerase I antibody positivity, but also treatment with GC independently of other factors.
A Century of Colon and Rectal Surgery at Mayo Clinic (1924–2024): Honoring Our Founder Louis A. Buie Sr., M.D., D.Sc.
Kelley, Scott R. , Dozois, Eric J. , Kelley, Scott R

Mayo Clinic

Diseases of the Colon & Rectum | March 5, 2024 | Volume: 67 | Issue: 6 | Pages: 755-761

10.1097/dcr.0000000000003314 | PMID 38441192 Get It

Novel radiotherapeutic strategies in the management of brain metastases: Challenging the dogma
Perlow, Haley K. , Lehrer, Eric J. , Wardak, Zabi , Soliman, Hany , Palmer, Joshua D , Perlow, Haley K , Palmer, Joshua D.

Mayo Clinic

Neuro-Oncology | March 4, 2024 | Volume: 26 | Issue: Supplement_1 | Pages: S46-S55

10.1093/neuonc/noad260 | PMID 38437668 Get It

Abstract The role of radiation therapy in the management of brain metastasis is evolving. Advancements in machine learning techniques have improved our ability to both detect brain metastasis and our ability to contour substructures of the brain as critical organs at risk. Advanced imaging with PET tracers and magnetic resonance imaging-based artificial intelligence models can now predict tumor control and differentiate tumor progression from radiation necrosis. These advancements will help to optimize dose and fractionation for each patient’s lesion based on tumor size, histology, systemic therapy, medical comorbidities/patient genetics, and tumor molecular features. This review will discuss the current state of brain directed radiation for brain metastasis. We will also discuss future directions to improve the precision of stereotactic radiosurgery and optimize whole brain radiation techniques to improve local tumor control and prevent cognitive decline without forming necrosis.
HLA-DQB1*05 subtypes and not DRB1*10:01 mediates risk in anti-IgLON5 disease
Yogeshwar, Selina , Muñiz‐Castrillo, Sergio , Sabater, Lídia , Peris-Sempere, Vicente, Mallajosyula, Vamsee , Guo, Luo, Yan, Han , Lin, Ling , Bueno, Flavia Fagundes, Ji, Xuhuai , Picard, Géraldine , Pinto, Anne Laurie, Heidbreder, Anna , Dalmau, Josep , Santamaría, Joan , Iranzo, Alex, Schreiner, Bettina , Giannoccaro, Maria Pia , Kimura, Akio , Ono, Yoya , Bonello, Michael , Nigro, Pasquale , Prüß, Harald , McKeon, Andrew, Irani, Sarosh R. , Gaig, Carles , Mignot, Emmanuel , Luo, Guo , Yogeshwar, Selina M , Höftberger, Romana , Iranzo, Alex , Dinoto, Alessandro , Irani, Sarosh R , Honnorat, Jérôme , Finke, Carsten , Mignot, Emmanuel , Muñiz-Castrillo, Sergio , Dalmau, Josep O , Heidbreder, Anna , Luo, Guo, Yu, Eric , Zhang, Jing , Rogemond, Véronique , Graus, Francesc , Liguori, Rocco , Shimohata, Takayoshi , Binks, Sophie , Mariotto, Sara , Dinoto, Alessandro , Hartmann, Christian Johannes , Tambasco, Nicola , McKeon, Andrew , Davis, Mark M. , Honnorat, Jérôme

Mayo Clinic

Brain | March 1, 2024 | Volume: 147 | Issue: 7 | Pages: 2579-2592

10.1093/brain/awae048 | PMID 38425314 Get It

Abstract Anti-IgLON5 disease is a rare and likely underdiagnosed subtype of autoimmune encephalitis. The disease displays a heterogeneous phenotype that includes sleep, movement and bulbar-associated dysfunction. The presence of IgLON5-antibodies in CSF/serum, together with a strong association with HLA-DRB1*10:01∼DQB1*05:01, supports an autoimmune basis. In this study, a multicentric human leukocyte antigen (HLA) study of 87 anti-IgLON5 patients revealed a stronger association with HLA-DQ than HLA-DR. Specifically, we identified a predisposing rank-wise association with HLA-DQA1*01:05∼DQB1*05:01, HLA-DQA1*01:01∼DQB1*05:01 and HLA-DQA1*01:04∼DQB1*05:03 in 85% of patients. HLA sequences and binding cores for these three DQ heterodimers were similar, unlike those of linked DRB1 alleles, supporting a causal link to HLA-DQ. This association was further reflected in an increasingly later age of onset across each genotype group, with a delay of up to 11 years, while HLA-DQ-dosage dependent effects were also suggested by reduced risk in the presence of non-predisposing DQ1 alleles. The functional relevance of the observed HLA-DQ molecules was studied with competition binding assays. These proof-of-concept experiments revealed preferential binding of IgLON5 in a post-translationally modified, but not native, state to all three risk-associated HLA-DQ receptors. Further, a deamidated peptide from the Ig2-domain of IgLON5 activated T cells in two patients, compared with one control carrying HLA-DQA1*01:05∼DQB1*05:01. Taken together, these data support a HLA-DQ-mediated T-cell response to IgLON5 as a potentially key step in the initiation of autoimmunity in this disease.
Metal artifact reduction sequence-MRI abnormalities in asymptomatic patients with dual-mobility hip prostheses
Chung, Brian , Liu, Kevin C. , Chen, Xiao T. , Lovro, Luke R. , Kistler, Natalie M. , Longjohn, Donald B. , Oakes, Daniel A. , Lieberman, Jay R. , Lovro, Luke R , Heckmann, Nathanael D. , White, Eric A. , Christ, Alexander B.

Mayo Clinic

The Bone & Joint Journal | March 1, 2024 | Volume: 106-B | Issue: 3 Supple A | Pages: 89-96

10.1302/0301-620x.106b3.bjj-2023-0643.r1 | PMID 38423076 Get It

AimsModular dual-mobility (DM) articulations are increasingly used during total hip arthroplasty (THA). However, concerns remain regarding the metal liner modularity. This study aims to correlate metal artifact reduction sequence (MARS)-MRI abnormalities with serum metal ion levels in patients with DM articulations.MethodsA total of 45 patients (50 hips) with a modular DM articulation were included with mean follow-up of 3.7 years (SD 1.2). Enrolled patients with an asymptomatic, primary THA and DM articulation with over two years’ follow-up underwent MARS-MRI. Each patient had serum cobalt, chromium, and titanium levels drawn. Patient satisfaction, Oxford Hip Score, and Forgotten Joint Score-12 (FJS-12) were collected. Each MARS-MRI was independently reviewed by fellowship-trained musculoskeletal radiologists blinded to serum ion levels.ResultsOverall, two patients (4.4%) had abnormal periprosthetic fluid collections on MARS-MRI with cobalt levels > 3.0 μg/l. Four patients (8.9%) had MARS-MRI findings consistent with greater trochanteric bursitis, all with cobalt levels < 1.0 μg/l. A seventh patient had a periprosthetic fluid collection with normal ion levels. Of the 38 patients without MARS-MRI abnormalities, 37 (97.4%) had cobalt levels < 1.0 μg/l, while one (2.6%) had a cobalt level of 1.4 μg/l. One patient (2.2%) had a chromium level > 3.0 μg/l and a periprosthetic fluid collection. Of the 41 patients with titanium levels, five (12.2%) had titanium levels > 5.0 μg/l without associated MARS-MRI abnormalities.ConclusionPeriprosthetic fluid collections associated with elevated serum cobalt levels in patients with asymptomatic DM articulations occur infrequently (4.4%), but further assessment is necessary due to implant heterogeneity.Cite this article: Bone Joint J 2024;106-B(3 Supple A):89–96.
Fracture risk based on high-resolution peripheral quantitative computed tomography measures does not vary with age in older adults—the bone microarchitecture international consortium prospective cohort study
Szulc, Paweł , Hannan, Marian T. , Merle, Blandine , Boyd, Steven K. , Hanley, David A. , Lespessailles, Éric , Bouxsein, Mary , Hannan, Marian T , Lespessailles, Eric , Szulc, Pawel , Boyd, Steven K , Dufour, Alyssa B , Kiel, Douglas P. , Chapurlat, Roland D , Sornay‐Rendu, Elisabeth , Whittier, Danielle E. , Goltzman, David , Wong, Andy Kin On , Khosla, Sundeep , Ferrari, Serge , Biver, Emmanuel , Samelson, Elizabeth J

Mayo Clinic

Journal of Bone and Mineral Research | February 29, 2024 | Volume: 39 | Issue: 5 | Pages: 561-570

10.1093/jbmr/zjae033 | PMID 38477737 Get It

Abstract Fracture risk increases with lower areal bone mineral density (aBMD); however, aBMD-related estimate of risk may decrease with age. This may depend on technical limitations of 2-dimensional (2D) dual energy X-ray absorptiometry (DXA) which are reduced with 3D high-resolution peripheral quantitative computed tomography (HR-pQCT). Our aim was to examine whether the predictive utility of HR-pQCT measures with fracture varies with age. We analyzed associations of HR-pQCT measures at the distal radius and distal tibia with two outcomes: incident fractures and major osteoporotic fractures. We censored follow-up time at first fracture, death, last contact or 8 years after baseline. We estimated hazard ratios (HR) and 95%CI for the association between bone traits and fracture incidence across age quintiles. Among 6835 men and women (ages 40–96) with at least one valid baseline HR-pQCT scan who were followed prospectively for a median of 48.3 months, 681 sustained fractures. After adjustment for confounders, bone parameters at both the radius and tibia were associated with higher fracture risk. The estimated HRs for fracture did not vary significantly across age quintiles for any HR-pQCT parameter measured at either the radius or tibia. In this large cohort, the homogeneity of the associations between the HR-pQCT measures and fracture risk across age groups persisted for all fractures and for major osteoporotic fractures. The patterns were similar regardless of the HR-pQCT measure, the type of fracture, or the statistical models. The stability of the associations between HR-pQCT measures and fracture over a broad age range shows that bone deficits or low volumetric density remain major determinants of fracture risk regardless of age group. The lower risk for fractures across measures of aBMD in older adults in other studies may be related to factors which interfere with DXA but not with HR-pQCT measures.
Clopidogrel and Percutaneous Coronary Interventions—Reply
Steinhubl, Steven R., Berger, Peter B. , Mann, Jessica, Fry, Edward T.A., DeLago, Augustin , Wilmer, Charles, Topol, Eric J.

Mayo Clinic

JAMA | February 28, 2024 | Volume: 289 | Issue: 15 | Pages: 1926

10.1001/jama.289.15.1925-f Get It